SCHEMBL4937577

SCHEMBL4937577

CS(=O)(=O)c1ccc(-c2ccccc2)c(C(=O)N2CCN(c3ccc(Cl)c(Cl)c3)CC2)c1

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 11/20 0.71
HTT P42858 2/20 0.51
MAPT P10636 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.51
GPR55 Q9Y2T6 4/20 0.51
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4938243 0.92 SLC6A9 (0.61) SLC6A9HTTMAPTSMN1; SMN2ALDH1A1
SCHEMBL4943566 0.91 SLC6A9 (0.59) SLC6A9HTTMAPTSMN1; SMN2ALDH1A1
SCHEMBL4943084 0.90 SLC6A9 (0.60) SLC6A9HTTMAPTSMN1; SMN2ALDH1A1
SCHEMBL4941678 0.90 SLC6A9 (0.73) SLC6A9HTTMAPTSMN1; SMN2ALDH1A1
SCHEMBL4948280 0.90 SLC6A9 (0.68) SLC6A9ALDH1A1TSHRGPR55
SCHEMBL4942303 0.89 SLC6A9 (0.58) SLC6A9HTTMAPTSMN1; SMN2ALDH1A1
SCHEMBL4434158 0.88 SLC6A9 (0.80) SLC6A9ALDH1A1LMNATSHRGPR55
SCHEMBL4936345 0.87 SLC6A9 (0.65) SLC6A9TSHRGPR55ALOX15
SCHEMBL4930270 0.87 SMN1; SMN2 (0.59) SLC6A9HTTMAPTSMN1; SMN2ALDH1A1
SCHEMBL4423440 0.86 SLC6A9 (0.78) SLC6A9GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
EP-1858869-A1 ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors SLC1A1, SLC6A7, SLC1A2 SLC6A9 9/4885HTT 417/4885MAPT 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.